Metabasis Therapeutics, Inc. (Nasdaq: MBRX), a biopharmaceutical company
focused on innovative therapies for metabolic diseases including
hyperlipidemia and diabetes, today announced that it will hold a
conference call to discuss the Company’s first quarter financial results.
Mark Erion, Ph.D., president, chief executive officer and chief
scientific officer, Tran Nguyen, M.B.A., vice president and chief
financial officer, and Barry Gumbiner, M.D., vice president of clinical
development and chief medical officer, will host the call beginning at
8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Friday, May 15, 2009.
A press release for the first quarter financial results will be released
after market close on May 14th.
To participate in the live call by telephone, please dial 866-510-0710
from the U.S. or 617-597-5378 for international callers. Please specify
to the operator “Metabasis” when asked for a passcode. In addition, the
live conference call is being webcast and can be accessed on the
Metabasis website at www.mbasis.com,
under the Investors section, and will be archived there for 30 days
following the call. Please connect to the Metabasis website several
minutes prior to the start of the call to ensure adequate time for any
software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis is a biopharmaceutical company using its proprietary
technologies, scientific expertise and unique capabilities for targeting
the liver and liver pathways to develop novel therapies to treat
metabolic and other diseases. The Company has established a broad
pipeline of product candidates and advanced discovery programs targeting
large markets with significant unmet needs. Metabasis' core area of
focus is on the discovery and development of drug candidates to treat
metabolic diseases including hyperlipidemia and diabetes. Although not a
core focus of the Company, Metabasis has also discovered and developed
drug candidates for the treatment of liver diseases such as hepatitis
and primary liver cancer, which it now intends to license or partner.
All product candidates were developed internally using proprietary
technologies and know how.
Metabasis Therapeutics, Inc.
Investor Relations & Corporate
Communications
858-622-2223
